BioNTech SE (NASDAQ:BNTX) is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an independent monitoring committee concluded that continuing the trial was unlikely to demonstrate effectiveness. The decision is more concerning than a routine trial...
ca.finance.yahoo.com